Home Institutions Mount Sinai clinical trials Institution Directory
Clinical trials at Mount Sinai Sites in New York, NY
Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.
ClinicalTrials.gov public records Last synced Oct 22, 2026, 12:46 AM EDT
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official matching trials
1097
Current sort
Recently updated
Campus scope
Mount Sinai, New York, NY
Additional filters apply within this campus.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Showing 361–372 of 1,097 matching trials with a site at Mount Sinai, New York, NY.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.
Live official records
Conditions Alzheimer Disease
Interventions Low Dose Benfotiamine, High Dose Benfotiamine, Placebo Drug
Lead sponsor Weill Medical College of Cornell University Other
Eligibility 50 Years to 89 Years
Enrollment 406 participants
Healthy volunteers Healthy volunteers not accepted
Timeline 2024 – 2027
U.S. locations 47
States / cities Phoenix, Arizona • Scottsdale, Arizona • Sun City, Arizona + 35 more
Conditions Liver Transplant
Interventions Everolimus, Tacrolimus (continued reduction), Tacrolimus (maintain 50% reduction) Drug
Lead sponsor National Institute of Allergy and Infectious Diseases (NIAID) NIH
Eligibility 18 Years and older
Enrollment 340 participants
Healthy volunteers Healthy volunteers not accepted
Timeline 2024 – 2030
U.S. locations 12
States / cities Phoenix, Arizona • Los Angeles, California • San Diego, California + 9 more
Conditions Multiple Myeloma, Plasma Cell Disorder
Interventions HDP-101 Drug
Lead sponsor Heidelberg Pharma AG Industry
Eligibility 18 Years and older
Enrollment 78 participants
Healthy volunteers Healthy volunteers not accepted
Timeline 2022 – 2028
U.S. locations 5
States / cities Atlanta, Georgia • Louisville, Kentucky • Omaha, Nebraska + 2 more
Conditions Aortic Stenosis
Interventions ACURATE neo2™ Transfemoral TAVR System, Medtronic CoreValve TAVR System, Edwards SAPIEN 3 TAVR System, ACURATE Prime™ Transfemoral TAVR System XL Device
Lead sponsor Boston Scientific Corporation Industry
Eligibility Not listed
Enrollment 1,948 participants
Healthy volunteers Healthy volunteers not accepted
Timeline 2019 – 2029
U.S. locations 69
States / cities Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 58 more
Conditions PIDs Linked to PI3K
Interventions Leniolisib Drug
Lead sponsor Pharming Technologies B.V. Industry
Eligibility 12 Years to 75 Years
Enrollment 12 participants
Healthy volunteers Healthy volunteers not accepted
Timeline 2025 – 2029
U.S. locations 3
States / cities Bethesda, Maryland • Burlington, Massachusetts • New York, New York
Conditions NSCLC
Interventions REGN5093 Drug
Lead sponsor Regeneron Pharmaceuticals Industry
Eligibility 18 Years and older
Enrollment 95 participants
Healthy volunteers Healthy volunteers not accepted
Timeline 2020 – 2027
U.S. locations 8
States / cities Orange, California • Washington D.C., District of Columbia • Tampa, Florida + 4 more
Conditions Painful Peripheral Neuropathy, Diabetic Peripheral Neuropathic Pain (DPN), Chemotherapy Induced Peripheral Neuropathy (CIPN), Idiopathic Peripheral Neuropathy
Interventions Pregabalin, Duloxetine, Placebo Drug · Other
Lead sponsor University of Rochester Other
Eligibility 18 Years to 80 Years
Enrollment 190 participants
Healthy volunteers Healthy volunteers not accepted
Timeline 2026 – 2028
U.S. locations 7
States / cities Boston, Massachusetts • New York, New York • Rochester, New York + 4 more
Conditions Heart Failure With Preserved Ejection Fraction, Heart Failure With Mildly Reduced Ejection Fraction, Obesity
Interventions Maridebart cafraglutide, Placebo Drug
Lead sponsor Amgen Industry
Eligibility 18 Years to 99 Years
Enrollment 5,056 participants
Healthy volunteers Healthy volunteers not accepted
Timeline 2025 – 2030
U.S. locations 121
States / cities Birmingham, Alabama • Dothan, Alabama • Fairhope, Alabama + 107 more
Conditions Multiple Acyl-CoA Dehydrogenase Deficiency
Interventions Not listed
Lead sponsor Icahn School of Medicine at Mount Sinai Other
Eligibility Not listed
Enrollment 50 participants
Healthy volunteers Healthy volunteers not accepted
Timeline 2026 – 2031
U.S. locations 2
States / cities Aurora, Colorado • New York, New York
Conditions Peanut Allergy
Interventions Tezepelumab, Peanut Oral Immunotherapy (OIT), Placebo for Tezepelumab Biological · Drug
Lead sponsor National Institute of Allergy and Infectious Diseases (NIAID) NIH
Eligibility 12 Years to 55 Years
Enrollment 62 participants
Healthy volunteers Healthy volunteers not accepted
Timeline 2026 – 2029
U.S. locations 10
States / cities Little Rock, Arkansas • Los Angeles, California • Baltimore, Maryland + 6 more
Conditions Small Cell Lung Cancer Metastatic or Locally Advanced, Neuroendocrine Cancer, Metastatic Neuroendocrine Prostate Cancer, Metastatic Advanced Poorly Differentiated Gastroenteropancreatic Neuroendocrine Carcinoma, Metastatic Advanced Merkel Cell Carcinoma, Locally Advanced Large Cell Neuroendocrine Carcinoma of the Lung, Locally Advanced Extrapulmonary Neuroendocrine Carcinoma, Locally Advanced Neuroendocrine Prostate Cancer, Locally Advanced Poorly Differentiated Gastroenteropancreatic Neuroendocrine, Locally Advanced Merkel Cell Carcinoma, Metastatic Large Cell Neuroendocrine Carcinoma of the Lung
Interventions BL-M14D1 Drug
Lead sponsor SystImmune Inc. Industry
Eligibility 18 Years and older
Enrollment 120 participants
Healthy volunteers Healthy volunteers not accepted
Timeline 2025 – 2027
U.S. locations 24
States / cities Huntsville, Alabama • Glendale, California • Long Beach, California + 18 more
Conditions Bladder Cancer, Squamous Cell Carcinoma of the Lung, Esophageal Squamous Cell Carcinoma, Tongue Squamous Cell Carcinoma, Cutaneous Squamous Cell Cancer, Penile Squamous Cell Carcinoma, Anal Squamous Cell Carcinoma, Vulvar Squamous Cell Carcinoma, Cervical Squamous Cell Carcinoma, Vaginal Squamous Cell Carcinoma, Urethral Squamous Cell Carcinoma
Interventions EVOLVE104 Drug
Lead sponsor EvolveImmune United, Inc Industry
Eligibility 18 Years and older
Enrollment 160 participants
Healthy volunteers Healthy volunteers not accepted
Timeline 2025 – 2031
U.S. locations 16
States / cities Duarte, California • Los Angeles, California • San Francisco, California + 10 more About this Mount Sinai institution page
What this page lists ClinicalTrials.gov records that list Mount Sinai in New York, NY as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.
Related: all institution pages , browse by condition , or browse by U.S. city .